Clinical Pharmacology podcasts

Alexandra Delbot échange avec Karine Clément et Christophe Magnan sur les médicaments analogues du GLP-1. L’épisode retrace leur développement contre le diabète, leur utilisation dans le traitement de l’obésité et les mécanismes de réduction de l’appétit. Les intervenants discutent les bénéfices, effets et risques associés, ainsi que le détournement à visée esthétique et ses conséquences pour la santé.

Hosted by Alexandra Delbot

Saloni Dattani and Jacob Trefethen discuss siRNA medicines that suppress production of harmful proteins without changing DNA. They examine the long path from discovery to treatment, why existing drugs concentrate on liver diseases, programmable and long-lasting effects, and prospects and limitations for treating infection, cardiovascular disease, rare disorders and cancer.

Hosted by Saloni Dattani, Jacob Trefethen

Jennie Erin Smith discusses research on noninvasive brain stimulation in women’s health, including postpartum depression, menstrual pain and fertility-related questions. Liisa Galea reviews the evidence on hormone therapy during perimenopause and associations between menopausal symptoms and later health outcomes, including dementia and cardiovascular disease. The discussion concerns research findings and open questions rather than individual treatment recommendations.

Hosted by Sarah Crespi

Francesca and Ilaria discuss taste-receptor research, mitochondrial biology and a reported ALS case study involving an antisense oligonucleotide treatment. Giuliana Galati interviews University of Padua physicist Francesco Recchia about nuclear phenomenology. The episode links these discussions to the underlying research papers and distinguishes a clinical case report from established treatment evidence.

Hosted by Francesca Cecilia Lauta, Ilaria Zanardi

Scientific American's Science Quickly examines an early pilot trial of psilocybin-assisted therapy for people with long-term anorexia. The episode carefully discusses reported changes in symptoms and motivation, possible neuroplasticity mechanisms, the small uncontrolled sample and the need for larger randomized studies and clinical safeguards.

Tor-Morten Kvam discusses research into psychedelic-assisted treatment of mental illness and the history of this field. Conversation in Norwegian.